FDA delays decision on Risperdal Consta to treat bipolar disorder

02/10/2009 | Bloomberg · Forbes

Seeking more information, the FDA postponed its decision on the use of Johnson & Johnson's Risperdal Consta to treat frequent mood swings in patients with bipolar disorder. The product received FDA clearance in 2003 as a twice-a-month treatment for schizophrenia.

View Full Article in:

Bloomberg · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA